About: Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19)
Creator	Li, Xiaokun Chen, Dong Zhang, Xiaoming Huang, Jianping Dai, Jianyi »more»
source	MedRxiv
abstract	BACKGROUND: SARS-CoV-2 has caused a series of COVID-19 globally. SARS-CoV-2 binds angiotensin I converting enzyme 2 (ACE2) of renin-angiotensin system (RAS) and causes prevalent hypokalemia METHODS: The patients with COVID-19 were classified into severe hypokalemia, hypokalemia, and normokalemia group. The study aimed to determine the relationship between hypokalemia and clinical features, the underlying causes and clinical implications of hypokalemia. RESULTS: By Feb 15, 2020, 175 patients with COVID-19 (92 women and 83 men; median age, 46 [IQR, 34-54] years) were admitted to hospital in Wenzhou, China, consisting 39 severe hypokalemia-, 69 hypokalemia-, and 67 normokalemia patients. Gastrointestinal symptoms were not associated with hypokalemia among 108 hypokalemia patients (P>0.05). Body temperature, CK, CK-MB, LDH, and CRP were significantly associated with the severity of hypokalemia (P<0.01). 93% of severe and critically ill patients had hypokalemia which was most common among elevated CK, CK-MB, LDH, and CRP. Urine K+ loss was the primary cause of hypokalemia. severe hypokalemia patients was given 3 g/day, adding up to an average of 34 (SD=4) g potassium during hospital stay. The exciting finding was that patients responded well to K+ supplements when they were inclined to recovery. CONCLUSIONS: Hypokalemia is prevailing in patients with COVID-19. The correction of hypokalemia is challenging because of continuous renal K+ loss resulting from the degradation of ACE2. The end of urine K+ loss indicates a good prognosis and may be a reliable, in-time, and sensitive biomarker directly reflecting the end of adverse effect on RAS system.
has issue date	2020-02-29(xsd:dateTime)
bibo:doi	10.1101/2020.02.27.20028530
has license	medrxiv
sha1sum (hex)	264a816e7099246c13a5dad3a581a474d85d50bd
schema:url	https://doi.org/10.1101/2020.02.27.20028530
resource representing a document's title	Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19)
resource representing a document's body	covid:264a816e7099246c13a5dad3a581a474d85d50bd#body_text
is schema:about of	named entity 'binds' named entity 'Hypokalemia' named entity 'HYPOKALEMIA' named entity 'PREVALENT' covid:arg/264a816e7099246c13a5dad3a581a474d85d50bd »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software